STOCKHOLM, 12 may 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish the interim report for the first quarter of 2017, 16 may 2017, after the market closed. The company will also hold a conference call and web presentation 17 may at 14.00 CEST.
Please call on any of the following numbers a few minutes before telefonkonferensens start:
-
From Sweden: +46 (0) 8 505 564 74
-
From the USA: +1 855 753 22 30
-
From The Uk: +44 (0) 20 336 453 74
Webbpresentationen can simultaneously be accessed from:
http://edge.media-server.com/m/p/5uihaf3q
Presenter: Jim Van heusden, PRESIDENT.
For further information, please contact the
:
Jim Van heusden, CEO, Karolinska Development AB
Tel: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com
Christian Tange, cfo, Karolinska Development AB
Tel: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Tel: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a nordic investment company in the field of life science. The company focuses on identifying the medical innovations and to invest in order to create and develop companies that develop such innovations into differentiated products that can make a difference to patients ‘ lives, and generate an attractive return to shareholders.
Karolinska Development has access to medical research in the world from Karolinska Institutet and other leading universities and research institutions in the Nordic countries. The company’s goal is to build a company around researchers who are leaders in their respective fields of science, with support from the experienced management teams and advisors, and funding with international investors specialized in the sector. In order to create the best opportunities for success built businesses with experienced management team and advisors and co-financed by the professional life-science investors.
Karolinska Development portfolio consists of nine companies focused on developing innovative treatments for diseases that are life-threatening or debilitating, and other medical conditions.
The company is managed by a entreprenörsteam consisting of investment professionals with extensive experience in company-building and with access to a strong global network.
For more information: www.karolinskadevelopment.com.
This information is such information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to publish according to the act on trading in financial instruments. The information was submitted by Jim Van heusden for publication on may 12, 2017, at 08:00.
Karolinska Development Q1 2017 Invitation PR (SWE)